The HERIZON-GEA-01 trial provides clinicians with important evidence to inform treatment decisions for HER2-positive gastroesophageal cancer. First, zanidatamab demonstrates substantial progression-free survival improvements at both 12 and 18 months, with 56% of patients remaining progression-free at 18 months compared to 36% with trastuzumab—translating to clinically meaningful extended survival periods. Second, the mechanism of action—dual HER2 epitope targeting—offers theoretical advantages in overcoming resistance mechanisms associated with conventional monoclonal antibodies. Third, the manageable safety profile with low cardiac toxicity concerns makes zanidatamab a viable option for broader patient populations. These findings suggest that zanidatamab warrants consideration as a potential new standard for first-line treatment in this disease setting. Clinicians are encouraged to review full trial data and safety analyses when evaluating this emerging therapeutic option.
Read the full article on GMJ Newsroom.
Was this article helpful?
